USPTO Art Unit 1624 Prosecution Statistics

Art Unit Information

Art Unit: 1624
Group: 1620
Tech Center: 1600
Total Cases: 28,512
Last Active: March 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19069098MACROCYCLIC DERIVATIVE AND USE THEREOFMarch 2025June 2025Allow301NoNo
19052553THRB RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD AND USE THEREOFFebruary 2025June 2025Allow410NoNo
19016827SUBSTITUTED QUINAZOLINES AS HDAC6 INHIBITORSJanuary 2025July 2025Allow610YesNo
19015403SUBSTITUTED PYRIDO[4,3-d]PYRIMIDINES AS KRAS MODULATORSJanuary 2025July 2025Allow610YesNo
18973867N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATIONDecember 2024May 2025Allow610NoNo
18972557BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERSDecember 2024April 2025Allow501NoNo
18948031CRYSTALLINE FORMS OF 4-ETHOXY-N-(2-METHOXYETHYL)-N-METHYL-3-(5-METHYL-4-OXO-7-PROPYL-3,4-DIHYDROIMIDAZO[5,1-f][1,2,4]TRIAZIN-2-YL)BENZENESULFONAMIDENovember 2024February 2025Allow310YesNo
18934931THIAZOLE COMPOUNDS AND METHODS OF USE THEREOFNovember 2024February 2025Allow401NoNo
18927756BENZOTRIAZOLE COMPOUNDOctober 2024March 2025Allow510NoNo
18917653NLRP3 INFLAMMASOME INHIBITORSOctober 2024March 2025Allow511YesNo
18884381AMIDO HETEROAROMATIC COMPOUNDSSeptember 2024March 2025Allow611NoNo
188826491,4-DIHYDROQUINAZOLINONE COMPOUNDS AND USES THEREOFSeptember 2024February 2025Allow501NoNo
18820993PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTAugust 2024February 2025Allow510NoNo
18723033SUBSTITUTED MORPHOLINES AS ATR KINASE INHIBITORSAugust 2024June 2025Allow1211YesNo
18838246C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCERAugust 2024April 2025Allow811NoNo
18804311NOVEL SUBSTITUTED PYRAZINE-CARBOXAMIDE DERIVATIVESAugust 2024January 2025Allow511YesNo
18800565IMIDAZOLO DERIVATIVES, COMPOSITIONS AND METHODS AS OREXIN ANTAGONISTSAugust 2024November 2024Allow311NoNo
18832297PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6-CONTAINING MULTI- COMPONENT MATERIALJuly 2024April 2025Allow910NoNo
18832315PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM NYLON 6 COMPRISING FISHING NETSJuly 2024April 2025Allow910NoNo
18832305PROCESS FOR THE RECOVERY OF EPSILON-CAPROLACTAM FROM POLYAMIDE 6 COMPRISING FISHING NETSJuly 2024March 2025Allow800NoNo
18778527HETEROCYCLIC COMPOUNDS AND USES THEREOFJuly 2024October 2024Allow311NoNo
18777202PARP1 INHIBITORS AND USES THEREOFJuly 2024December 2024Allow510NoNo
18775819FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOFJuly 2024May 2025Allow911NoNo
18764004CRYSTALLINE SALT FORMS OF KAPPA OPIOID RECEPTOR ANTAGONIST AND PRODUCTS AND METHODS RELATED THERETOJuly 2024August 2024Allow200NoNo
18724932PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTSJune 2024December 2024Allow601NoNo
18721449SUBSTITUTED PIPERIDINES AND PIPERAZINES AND METHODS FOR THE TREATMENT OF CNS DISORDERSJune 2024April 2025Allow1010YesNo
18741739PHARMACEUTICAL COMPOSITIONS COMPRISING 4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)-1-(4-((6bR,10aS)-3-METHYL-2,3,6b,9,10,10a-HEXAHYDRO-1H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-de]QUINOXALIN-8(7H)-YL)PHENYL)BUTAN-1-ONE FOR TREATING CONDITIONS OF THE CENTRAL NERVOUS SYSTEM AND CARDIAC DISORDERSJune 2024December 2024Allow710YesNo
18740233SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONSJune 2024May 2025Allow1101NoNo
187367105-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSJune 2024October 2024Allow510NoNo
18675780CRYSTALLINE SOLID FORMS OF A BET INHIBITORMay 2024July 2025Allow1310NoNo
18673619O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORSMay 2024December 2024Allow610YesNo
18668025HETEROCYCLIC COMPOUNDS AND USES THEREOFMay 2024July 2024Allow200NoNo
18661650HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERSMay 2024September 2024Allow411NoNo
18661225CRYSTALLINE FORM OF DEURUXOLITINIB PHOSPHATEMay 2024August 2024Allow300YesNo
18658960CRYSTAL FORM OF XEVINAPANT FOR TREATING LA SCCHNMay 2024July 2024Allow300YesNo
18653538SUBSTITUTED PYRIDINES AS PARP1 INHIBITORSMay 2024May 2025Allow1201YesNo
18652164SOLID FORMS OF ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION AND METHODS OF USE THEREOFMay 2024August 2024Allow410NoNo
18651408C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR InhibitorsApril 2024May 2025Allow1300NoNo
18650894TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINEApril 2024October 2024Allow610NoNo
18650932TOPICAL PHARMACEUTICAL COMPOSITION IN THE FORM OF AQUEOUS GEL COMPRISING AT LEAST AMITRIPTYLINEApril 2024October 2024Allow610NoNo
18645972CRYSTALLINE CHLORO-N-(4-(MORPHOLINOMETHYL)PHENYL)BENZAMIDE AND CRYSTALLINE HYDROCHLORIDE SALTApril 2024July 2024Allow310NoNo
18641842PHEBOX LIGANDS AND METHODS OF MAKING SAMEApril 2024December 2024Allow800NoNo
18639255POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4April 2024June 2024Allow200NoNo
18635839HETEROCYCLIC COMPOUNDApril 2024March 2025Allow1110NoNo
18634259NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOFApril 2024March 2025Abandon1120NoNo
18630109THERAPEUTIC COMPOUNDS AND METHODSApril 2024April 2025Allow1210NoNo
18627412SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORSApril 2024October 2024Allow711YesNo
18627407SUBSTITUTED PYRIMIDO[4,5-b]INDOLES AS CK2 INHIBITORSApril 2024March 2025Allow1111YesNo
186257161,3-BIS(NAPHTHALEN-1-YLOXY)PROPAN-2-ONE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)April 2024June 2024Allow200NoNo
18624178PROCESS FOR PREPARING SUBSTITUTED IMIDAZO[4,5-c]PYRAZOLESApril 2024August 2024Allow410YesNo
18623812BICYCLIC 1,4-DIAZEPANONES AND THERAPEUTIC USES THEREOFApril 2024April 2025Allow1210NoNo
186235445-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDApril 2024September 2024Allow510NoNo
186238085-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-1-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDApril 2024June 2024Allow300YesNo
18621266RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAMEMarch 2024June 2025Abandon1410NoNo
186188245-(SUBSTITUTEDPHENYL)-7-THIOXO-7,8-DIHYDROPYRIMIDO[4,5-d]PYRIMIDINE-2,4(1H,3H)-DIONE ANALOGUES AS ANTIBACTERIAL AGENTSMarch 2024November 2024Allow711YesNo
18612631FUSED IMIDAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOFMarch 2024December 2024Allow921NoNo
186116858-((4-HYDROXY-3-METHOXYPHENYL)DIAZENYL)NAPHTHALENE-1,3-DISULFONIC ACID AS AN ANTIOXIDANT COMPOUNDMarch 2024September 2024Allow610NoNo
18609790PHARMACEUTICAL COMPOSITIONSMarch 2024November 2024Allow811YesNo
18608756DOSAGE FORMS OF MIRDAMETINIBMarch 2024March 2025Abandon1210NoNo
18607834HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDSMarch 2024May 2025Abandon1410NoNo
18692791AHR INHIBITOR, USE THEREOF, AND PREPARATION METHOD THEREFORMarch 2024March 2025Abandon1321YesNo
18606890ANTI-CANCER COMPOSITION CONTAINING GOLD AND CYTOTOXIC AGENTMarch 2024August 2024Allow501NoNo
18606917CYTOTOXICITY ASSAY COMPOSITION AND GOLD (III) COMPLEXMarch 2024August 2024Allow501NoNo
18606361LIQUID PHARMACEUTICAL COMPOSITION OF GOLDMarch 2024August 2024Allow501NoNo
18606260SOLID PHARMACEUTICAL GOLD-BASED COMPOSITIONMarch 2024July 2024Allow501NoNo
18600352NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOFMarch 2024June 2024Allow300NoNo
18600347NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOFMarch 2024November 2024Abandon801NoNo
18596024MULTICYCLIC COMPOUNDSMarch 2024May 2024Allow300NoNo
18595206ASYMMETRIC ALLYL TRYPTAMINESMarch 2024October 2024Allow811YesNo
18688914COUPLED UREA MELAMINE PRODUCTION WITH HP CO2 STRIPPINGMarch 2024July 2024Allow400NoNo
18592808RAS INHIBITORSMarch 2024April 2025Allow1320NoNo
18688683THERAPEUTIC COCRYSTALS OF 3-{[5-(AZETIDINE-1-YLCARBONYL)PYRAZIN-2-YL]OXY}-5-{[(1S)-1-METHYL-2-(METHYLOXY)ETHYL]OXY)-N-(5-METHYLPYRAZIN-2-YL)BENZAMIDEMarch 2024March 2025Allow1311YesNo
18586620TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORSFebruary 2024August 2024Allow611YesNo
18584672PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTFebruary 2024February 2025Allow1210NoNo
18584177PYRAZOLOPYRIDINE DERIVATIVE HAVING GLP-1 RECEPTOR AGONIST EFFECTFebruary 2024March 2025Allow1310NoNo
18584440INDAZOLE COMPOUNDS AS KINASE INHIBITORSFebruary 2024May 2024Allow311NoNo
18584520Benzodiazepine Derivatives as RSV InhibitorsFebruary 2024December 2024Allow1010NoNo
18583002LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORSFebruary 2024April 2025Abandon1410NoNo
18582548CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USEFebruary 2024March 2025Abandon1310NoNo
18444006Compounds for the Treatment of Alzheimer's DiseaseFebruary 2024May 2025Allow1511NoNo
18435547N-[(4,6-DIMETHYLPYRIMIDIN-2-YL)CARBAMOTHIOYL] PYRIDINE-3-CARBOXAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.)February 2024August 2024Allow710YesNo
184346017-(4-((5-(2-CHLOROBENZYLIDENEAMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY COMPOUNDFebruary 2024April 2024Allow200YesNo
18434620PROCESS FOR MAKING (E)-7-(4-((5-((2-CHLOROBENZYLIDENE)AMINO)-2-THIOXO-1,3,4-THIADIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1-CYCLOPROPYL-6-FLUORO-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACIDFebruary 2024July 2024Allow610YesNo
184303972-(1H-IMIDAZOLE-1-CARBONYL)BENZOIC ACID AS AN ANTICANCER COMPOUNDFebruary 2024August 2024Allow610NoNo
18430456COMPOUNDS AND METHODS OF USEFebruary 2024September 2024Allow711NoNo
18430429COMPOUNDS AND METHODS OF USEFebruary 2024November 2024Allow1011NoNo
18430498AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORSFebruary 2024March 2025Allow1310NoNo
184304002-[(1H-BENZIMIDAZOL-2-YL)IMINO]-5,5-DIPHENYLIMIDAZOLIDIN-4-ONE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024August 2024Allow610NoNo
18427226CRYSTALLINE FORMS OF N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDEJanuary 2024July 2024Allow600YesNo
18423596TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND A CDK4/6 INHIBITORJanuary 2024January 2025Allow1210NoNo
18420017SUBSTITUTED PYRIMIDINES AS VACCINE ADJUVANTSJanuary 2024May 2025Allow1611NoNo
18417159PIPERIDINE DERIVATIVES AS METTL3 INHIBITORSJanuary 2024May 2024Allow401NoNo
18413744PYRIDO[3,4-E][1,2,4]TRIAZOLO[4,3-C]PYRIMIDINES AS CK2 INHIBITORSJanuary 2024August 2024Allow711NoNo
18413246SUBSTITUTED PYRIDO[4,3-e]PYRROLO[1,2-a]PYRAZINES AS CK2 INHIBITORSJanuary 2024July 2024Allow611YesNo
18414456COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETOJanuary 2024May 2025Abandon1601NoNo
17285491PROTEOLYSIS TARGETING CHIMERA (PROTACS) AS DEGRADERS OF SMARCA2 AND /OR SMARCA4January 2024August 2024Allow4010NoNo
18410925IMIDAZO[1,5-A]PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORSJanuary 2024March 2025Abandon1410NoNo
18409478SUBSTITUTED PIPERAZINES AS DOPAMINE D3/D2 RECEPTOR MODULATORSJanuary 2024July 2024Allow610NoNo
18393915SOLID STATE FORMS OF BELUMOSUDIL AND BELUMOSUDIL SALTSDecember 2023August 2024Allow711NoNo
183953295-SUBSTITUTED AMINOPYRIMIDO [6',1':2,3] IMIDAZO [4,5-C] [2,6] NAPHTHYRIDINE COMPOUNDS AS CK2 INHIBITORSDecember 2023April 2024Allow410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1624.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
67
Examiner Affirmed
47
(70.1%)
Examiner Reversed
20
(29.9%)
Reversal Percentile
36.8%
Lower than average

What This Means

With a 29.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1199
Allowed After Appeal Filing
455
(37.9%)
Not Allowed After Appeal Filing
744
(62.1%)
Filing Benefit Percentile
76.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 37.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Art Unit 1624 - Prosecution Statistics Summary

Executive Summary

Art Unit 1624 is part of Group 1620 in Technology Center 1600. This art unit has examined 28,512 patent applications in our dataset, with an overall allowance rate of 74.9%. Applications typically reach final disposition in approximately 22 months.

Comparative Analysis

Art Unit 1624's allowance rate of 74.9% places it in the 40% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.

Prosecution Patterns

Applications in Art Unit 1624 receive an average of 1.39 office actions before reaching final disposition (in the 17% percentile). The median prosecution time is 22 months (in the 87% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With fewer office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is shorter than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.